What distinguishes TB-500 from full-length Thymosin Beta-4?

TB-500 is a synthetic peptide corresponding to the actin-binding active region of the full 43-amino acid Thymosin Beta-4 protein. The TB-500 fragment retains the G-actin sequestration activity that drives cellular migration effects. Full-length Thymosin Beta-4 includes additional domains with other biological activities. Most preclinical research using TB-500 specifically targets the migration and wound healing mechanisms associated with the actin-binding domain.

How does TB-500 complement BPC-157 in repair research?

BPC-157 primarily acts on nitric oxide synthesis and VEGF-driven angiogenesis, addressing the vascular and growth factor dimensions of tissue repair. TB-500 primarily acts on actin sequestration and cellular migration, addressing the cytoskeletal and motility dimensions of wound closure. These two mechanisms are complementary and non-overlapping, which is why researchers studying the full repair cascade from revascularization through cellular migration often include both compounds.

Is Thymosin Beta-4 an endogenous compound?

Yes. Thymosin Beta-4 (T-beta-4) is an endogenous 43-amino acid peptide expressed in most mammalian cells. It is one of the most abundant intracellular proteins in many cell types and is released from platelets and macrophages following injury. TB-500 is a synthetic peptide corresponding to its active actin-binding fragment and is used in research to study the specific biological activities of this region.

What research models have examined TB-500?

TB-500 and Thymosin Beta-4 have been studied in corneal wound models, skin wound healing assays, rodent muscle and tendon injury paradigms, cardiac ischemia-reperfusion models, spinal cord injury protocols, and angiogenesis in vitro assays. The cardiac and wound healing literatures are the most developed, with multiple published studies from Smart et al. and associated groups examining cardiac progenitor cell activity.

Compound Reference

TB-500

A synthetic fragment of Thymosin Beta-4 studied for cellular migration, actin regulation, and systemic tissue repair.

Thymosin Beta-4 fragmentC₂₁₂H₃₅₀N₅₆O₇₈SApprox. 3 to 5 days (preclinical estimate)

Cellular MigrationWound ClosureMusculoskeletal RepairAngiogenesisCardiac Models

Overview

TB-500 is a synthetic peptide corresponding to the active region of Thymosin Beta-4 (T-beta-4), an endogenous 43-amino acid protein involved in actin sequestration, cytoskeletal regulation, and wound healing. The specific fragment studied as TB-500 includes the actin-binding domain responsible for G-actin sequestration, which modulates the actin polymerization state in cells undergoing migration or repair. Preclinical studies have examined TB-500 in wound healing, musculoskeletal injury, cardiac injury, and vascular remodeling models. Its systemic distribution characteristics make it a subject of interest in models where repair signaling needs to reach multiple tissues simultaneously.

Quick Reference

Active region: Thymosin Beta-4 fragment (actin-binding domain)
Key sequence: LKKTETQ (actin-binding motif)
Primary mechanism: G-actin sequestration, cellular migration modulation
Research models: Wound healing, cardiac, musculoskeletal, corneal
Purity standard: >=98% by HPLC

Mechanism

How It Works

TB-500 sequesters G-actin through its LKKTETQ actin-binding domain, reducing the free G-actin pool and thereby modulating actin polymerization dynamics. This influences cellular motility and cytoskeletal reorganization, promoting wound edge migration and tissue closure. TB-500 also has documented anti-inflammatory properties and promotes angiogenesis in preclinical wound and cardiac models.

Research Highlights

Key findings from the published preclinical literature.

Wound Closure and Cellular Migration

TB-500 has been studied for its ability to promote cellular migration at wound edges via actin sequestration, with corneal wound models and skin wound assays documenting accelerated closure relative to controls.

Cardiac Repair Models

Thymosin Beta-4 (and its active fragments including TB-500) has been investigated in cardiac injury models for its capacity to promote cardiomyocyte survival and cardiac progenitor cell migration following ischemic injury.

Musculoskeletal Injury Paradigms

Preclinical rodent models of muscle and tendon injury have documented TB-500 activity in reducing inflammatory signaling and supporting structural repair, complementary to the angiogenic mechanisms of co-studied compounds such as BPC-157.

Angiogenesis and Vessel Formation

TB-500 has been documented to promote endothelial cell migration and angiogenesis in in vitro and in vivo models, contributing to revascularization of injured tissue and supporting the wound healing cascade.

Research Connections

Related research areas, stacks, and comparisons involving this compound.

Frequently Asked Questions

Source This Compound

TB-500 is available from Spartan Peptides at a minimum 98% HPLC-verified purity with batch-specific certificate of analysis. Domestic US supply, same-day dispatch before 2 PM EST. For in-vitro research use only.

View TB-500 Product Sourcing Guide

All compounds are strictly for in-vitro research use only and not intended for human consumption.

GLP-3(Reta) | Triple-Agonist Metabolic Research

NAD+ 750mg | Cellular Energy & DNA Repair Research

MOTS-c | Mitochondrial Metabolism Research Peptide

BPC-157 5mg | Tissue Repair & Gut Health Research